(MENAFN- Straits Research)
Market Overview
The North America clinical laboratory tests market size was valued at USD 52.84 billion in 2025 and is projected to grow from USD 56.64 billion in 2026 to reach USD 98.79 billion by 2034, growing at a CAGR of 7.2% during the forecast period 2026–2034.
Clinical laboratories are healthcare institutions that provide physicians with a variety of laboratory tests, such as blood, urine, and other bodily fluid samples, to aid in the diagnosis, treatment, and management of patients. In these laboratories, medical technologists (clinical laboratory scientists) are trained to conduct a variety of tests on patients' biological specimens. The majority of clinical laboratories are situated within or close to hospital facilities to facilitate physician and patient access.
Download a Free Sample To learn more about this report,
Market Dynamics
North America Clinical Laboratory Tests Market Drivers
The largest market share for clinical laboratory tests was held by North America, and it is anticipated that this dominance will persist throughout the forecast period. The market is anticipated to be fueled by expanding regulatory support and rising investments in clinical laboratory tests. North America has advanced economies and a stringent regulatory framework for the approval of new tests. Under the 510(k) medical device regulation, the FDA has approved these tests. In order to be approved for commercialization, panel tests performed on instruments must undergo a similar FDA clearance process. Health Canada is responsible for approving these tests within Canada.
The market is expanding as a result of the high insurance coverage (nearly one hundred per cent) and the favorable regulatory measures. It is easier for patients to estimate costs when these tests are immediately billed to insurance companies. Medicaid provides coverage for urinalysis, blood tests, and screening exams. However, hospital fees in the area are higher than the cost of tests.
Ageing has become a significant risk factor for a variety of diseases, including obesity and diabetes, which both increase disease risk and cause metabolic imbalances. It is anticipated that the demand for clinical laboratory testing will increase as a result. According to the World Health Organization, life expectancy has surpassed 80 years in the majority of developed nations. Controlled by the interaction of multiple environmental and genetic factors that alter immunity, metabolism, and organ functions, ageing is a major risk factor for the development of infectious diseases. Consequently, screening and diagnostics can play a significant role in the overall management of health. As the global geriatric population grows, so does the demand for acute and long-term healthcare, driving the market for clinical laboratory testing.
The rising prevalence of lifestyle-related diseases such as obesity, the trend of smoking, and an unhealthy diet are among the factors contributing to the rise in renal and lipid-related disorders. In addition, as the incidence of diabetes rises, the number of patients requiring clinical laboratory tests increases. Increased sedentary behavior could lead to an increase in the prevalence of several metabolic diseases. In addition, according to the American Thyroid Association, 20 million people in the United States suffer from thyroidal imbalance. In the vast majority of nations, hormonal imbalance is a growing concern. Consequently, the market for clinical laboratory tests is anticipated to expand at a healthy rate throughout the period covered by this forecast.
Also likely to drive the market are hormone-dependent ageing disorders. According to the NCBI, the decline in female sex hormones following menopause is associated with disease and incapacity in older women. In 2016, approximately 27 million American women went through menopause, with that number rising to 31 million in 2018. This rise in target diseases is anticipated to fuel market expansion over the forecast period. The increased number of clinical laboratory tests can also be attributed to the increased awareness of certain diseases. In addition, the industry is supported by easy access to workplace testing and insurance-based exams.
North America Clinical Laboratory Tests Market Restraints
In the United States, the healthcare industry is highly dependent on regulatory frameworks established by the FDA and EMA. The Food and Drug Administration (FDA) regulates laboratory-designed tests (LDTs), which are tests created in-house by clinical laboratories that provide accurate and timely results. The risks associated with LDTs could reduce profit margins and cause marketing delays for newly designed tests. This factor is inhibiting the expansion of the clinical laboratory test market.
The spread of COVID-19 had a substantial impact on the healthcare and testing industries. The pandemic negatively impacted the clinical laboratory test market. In 2020, Lab Corporation, for instance, experienced an 8.9 per cent decline in total sales. This may be the result of a decline in routine health checkups during the pandemic, which led to a decrease in the number of clinical chemistry tests performed.
North America Clinical Laboratory Tests Market Opportunities
Innovative strategies for maximizing productivity and eradicating errors are anticipated to serve as a major rendering driver in this industry. Integrated workflow management systems, database management tools, and patient test records are gaining importance in the healthcare industry as organizations process between 100 and 150 billion samples annually. It is anticipated that the market will expand as a result of the implementation and development of data management and informatics solutions for supporting efficient operations.
In addition, the market is anticipated to expand during the forecast period as a result of the rising adoption of laboratory automation systems. Automation's advantages, such as its capacity to improve efficacy, reduce errors, and increase patient safety by combining mechanical, electronic, and informatics technologies, are anticipated to fuel market growth.
North America Clinical Laboratory Tests Market Segmental Analysis
By Type
The North America clinical laboratory tests market is segmented into complete blood count, basic metabolic panel, comprehensive metabolic panel, lipid panel, liver panel, renal panel, thyroid-stimulating hormone test, urinalysis, and others based on type. Complete blood count tests are widely used to evaluate overall health and identify conditions affecting blood cells. Basic and comprehensive metabolic panels are used to assess metabolic function and monitor key chemical levels in the body, while lipid panels help evaluate cholesterol and other blood lipid levels. Liver and renal panels support the assessment of liver and kidney function, respectively. Thyroid-stimulating hormone tests are used to evaluate thyroid function, while urinalysis is commonly performed to detect abnormalities associated with urinary and other health conditions. The others segment includes additional clinical laboratory tests used for routine screening, diagnosis, and disease monitoring.
Request Customization to receive a tailored report.
By Application
The North America clinical laboratory tests market is segmented into routine testing, infectious diseases, oncology, cardiology, endocrinology, and others based on application. Routine testing is widely performed for general health assessments, screening, and monitoring. Infectious disease testing supports the detection and management of bacterial, viral, and other infections. Oncology applications involve laboratory testing for cancer screening, diagnosis, treatment monitoring, and disease assessment. Cardiology testing helps evaluate cardiovascular health and identify conditions affecting the heart and circulatory system. Endocrinology applications include testing related to hormones, metabolism, and endocrine disorders. The others segment covers additional medical applications where laboratory testing supports diagnosis, monitoring, and clinical decision-making.
Speak to an Analyst to discuss market opportunities.
North America Clinical Laboratory Tests Market Regional Outlook
North America Clinical Laboratory Tests Market Analysis
North America is the dominant regional market for clinical laboratory tests, supported by advanced healthcare infrastructure, high demand for diagnostic testing, increasing prevalence of chronic diseases, and strong adoption of technologically advanced laboratory systems. The region also benefits from established regulatory frameworks, extensive insurance coverage, growing investments in laboratory automation, and increasing demand for early disease detection. The United States and Canada are the key countries contributing to regional market development.
United States Clinical Laboratory Tests Market Insights
The United States is the leading market for clinical laboratory tests in North America, supported by its advanced healthcare infrastructure, extensive diagnostic laboratory network, and high volume of laboratory testing. Rising prevalence of chronic diseases, an aging population, and increasing adoption of molecular diagnostics and automated laboratory technologies are driving demand. Strong investments in precision diagnostics and expanding access to preventive and screening tests are further supporting market growth.
Canada Clinical Laboratory Tests Market Insights
Canada is an important and growing market for clinical laboratory tests, supported by its universal healthcare system, expanding diagnostic infrastructure, and increasing demand for disease screening and early diagnosis. The aging population and rising prevalence of chronic conditions are contributing to higher testing volumes. Growing adoption of advanced diagnostic technologies and laboratory automation is also expected to support market development.
List of Key and Emerging Players in North America Clinical Laboratory Tests Market
Abbott
Quest Diagnostics
Laboratory Corporation of America
ARUP Laboratories
Key Industry Developments
June 2026: Labcorp expanded its clinical laboratory testing portfolio by advancing AI-enabled diagnostic workflows, automated laboratory operations, and precision medicine testing services. The company focused on improving turnaround times and supporting personalized healthcare across North America.
May 2026: Quest Diagnostics expanded its laboratory testing capabilities by introducing advanced molecular diagnostics, oncology testing, and digital laboratory solutions. The initiative focused on strengthening preventive care and precision diagnostics.
April 2026: Roche Diagnostics expanded its clinical laboratory portfolio by advancing high-throughput immunoassay and molecular testing platforms with enhanced laboratory automation and digital connectivity for hospitals and reference laboratories.
January 2026: Abbott expanded its diagnostics business by introducing next-generation clinical chemistry, immunoassay, and molecular diagnostic solutions designed to improve laboratory efficiency and diagnostic accuracy.
Report Scope
Comments
No comment